We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report.
- Authors
Masahiro Takeshima; Hiroyasu Ishikawa; Yuka Kikuchi; Takashi Kanbayashi; Tetsuo Shimizu
- Abstract
The management of clozapine (CLZ)-induced adverse events affects patient prognoses. Akathisia is a relatively rare adverse event related to CLZ administration and thus the management of this syndrome is not well established. Here, we report a case of treatment-resistant schizophrenia wherein CLZ-induced akathisia was successfully managed with gabapentin enacarbil (GE). The patient was a 39-year-old woman who had been treated with atypical antipsychotics other than CLZ for three years with poor tolerability. Initiation of CLZ (400 mg/day) attenuated her psychotic symptoms, but was followed by moderate akathisia. Neither benzodiazepines nor biperiden improved the akathisia; however, akathisia was finally diminished with co-administration of GE. GE facilitated a dosage increase in CLZ (450 mg/day) for the improved management of pyschotic symptoms, and thus indirectly contributed to treatment of the patient's schizophrenia. We suggest that GE is a useful candidate for the management of CLZ-induced akathisia. The improved management of treatment-induced akathisia and other adverse events can extend the potential application of CLZ for treatment-resistant schizophrenia.
- Subjects
TARDIVE akathisia; CLOZAPINE; GABAPENTIN
- Publication
Clinical Psychopharmacology & Neuroscience, 2018, Vol 16, Issue 3, p346
- ISSN
1738-1088
- Publication type
Article
- DOI
10.9758/cpn.2018.16.3.346